DHRC Stock Overview
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Danaher Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$231.40 |
| 52 Week High | US$247.60 |
| 52 Week Low | US$173.90 |
| Beta | 0.86 |
| 1 Month Change | 2.73% |
| 3 Month Change | 1.85% |
| 1 Year Change | 7.88% |
| 3 Year Change | 10.19% |
| 5 Year Change | n/a |
| Change since IPO | 86.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| DHRC | AT Life Sciences | AT Market | |
|---|---|---|---|
| 7D | 0.6% | 1.2% | 1.2% |
| 1Y | 7.9% | -11.6% | 5.9% |
Return vs Industry: DHRC exceeded the Austrian Life Sciences industry which returned -11.7% over the past year.
Return vs Market: DHRC exceeded the Austrian Market which returned 5.1% over the past year.
Price Volatility
| DHRC volatility | |
|---|---|
| DHRC Average Weekly Movement | 2.6% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in AT Market | 5.0% |
| 10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: DHRC has not had significant price volatility in the past 3 months.
Volatility Over Time: DHRC's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 62,000 | Rainer Blair | www.danaher.com |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.
Danaher Corporation Fundamentals Summary
| DHRC fundamental statistics | |
|---|---|
| Market cap | €171.48b |
| Earnings (TTM) | €3.79b |
| Revenue (TTM) | €22.09b |
45.4x
P/E Ratio7.8x
P/S RatioIs DHRC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DHRC income statement (TTM) | |
|---|---|
| Revenue | US$23.74b |
| Cost of Revenue | US$9.76b |
| Gross Profit | US$13.98b |
| Other Expenses | US$9.91b |
| Earnings | US$4.07b |
Last Reported Earnings
Mar 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.49 |
| Gross Margin | 58.89% |
| Net Profit Margin | 17.14% |
| Debt/Equity Ratio | 34.0% |
How did DHRC perform over the long term?
See historical performance and comparison